RecruitingBreast NeoplasmsLiver NeoplasmsMetastasis
A Multi-mode Thermophysical Immunotherapy Study for Breast Cancer Liver Metastases
Eligible age
18–75 yrs
Accepts
Women
Locations
0 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This is a single-center, parallel-controlled clinical study designed to evaluate the safety, efficacy and impact on systemic anti-tumor immunity of a multi-mode integrated ablation system for the treatment of breast cancer liver metastases.
Sponsor: Ruijin Hospital
You may qualify if…
- ✓ 1. Age 18-75 years, female gender;
- ✓ 2. Pathologically confirmed breast cancer liver metastases, in patients who are unable to tolerate or refuse surgical resection;
- ✓ 3. The number of lesions ≤ 3, with any single lesion diameter ≤ 4cm;
- ✓ 4. At least an interval of 1 month since the last local treatment;
- ✓ 5. Child-Pugh class A or B;
- ✓ 6. ECOG PS score ≤2, with an expected survival of \>3 months.
You may not qualify if…
- ✕ 1. Liver function Child-Pugh class C;
- ✕ 2. Systemic widespread metastasis, with an expected survival of \< 3 months;
- ✕ 3. History of esophageal (gastric fundus) variceal bleeding within the past month;
- ✕ 4. Dysfunction or failure of vital organs;
- ✕ 5. Presence of an active infection;
- ✕ 6. Irreparable coagulation abnormality;
- ✕ 7. Refractory massive ascites, pleural effusion or cachexia;
- ✕ 8. Pregnancy, altered consciousness or patients unable to cooperate with treatment;
Source: ClinicalTrials.gov · NCT06567353 · last updated 2025-03-14